Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance

BIODESIX INC

2023-Q2 EPS reported -$0.89 revenue$17,498,000

Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.
Net loss $15.8M, up 39% driven by loss on extinguishment from Indi contingent consideration restructuring.
Cash and equivalents $28.7M (incl. $5.1M restricted); raised net $27.3M in debt/equity during Q2.
Reaffirmed 2022 revenue outlook of $37.5M-$39.5M; Medicare coverage secured for Nodify CDT test.
Announced strategic pacts with Philips, MSK, and Bio-Rad to co-develop an MRD test for solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.